Neuralgia Drugs Market Share

  • Report ID: 3469
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Neuralgia Drugs Industry - Regional Synopsis

On the basis of geographical analysis, the neuralgia drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is likely to hold largest revenue share by 2037, on the back of increasing occurrence of diabetes and rising elderly population in the region. In addition, growing development of large specialty hospitals in countries namely China and India, is also projected to drive the region’s market growth in the coming years. Moreover, the market in North America is assessed to grab the largest share during the forecast period owing to the rising awareness associated with the availability of several treatment options, increase in healthcare spending and strong presence of prominent market players in the region. According to the National Health Expenditure Accounts (NHEA), total healthcare spending in the United States grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

Neuralgia Drugs Market size is poised to grow at over 6.3% CAGR during the forecast period i.e., between 2025-2037.

The market growth is impelled by growing prevalence of trigeminal neuralgia and increasing incidence rate of diabetes around the world.

Asia Pacific industry is likely to hold largest revenue share by 2037, on the back of increasing occurrence of diabetes and rising elderly population in the region.

The major players in the market are Pfizer, Inc., Novartis AG, Biogen Inc., Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos